FQHCs Reinvest 340B Savings in Safety-Net Care, JAMA Study Finds

Federally qualified health centers (FQHCs) appear to use their 340B program savings to enhance safety-net care, according to a new study in JAMA Health Forum.
Federally qualified health centers (FQHCs) appear to use their 340B program savings to enhance safety-net care, according to a new [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

ACA Played Key Role in 340B Growth, Drug Industry Consulting Firm Finds

IQVIA headquarters
An IQVIA analysis looked at the 340B program’s growth under the Affordable Care Act.
The 340B program has outgrown patient demands and requires additional restrictions and oversight, according to a new report from a [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Analysis Finds Growing Private Equity, Corporate Investments in 340B; Firm Conducting Study Fails to Mention Its Own PE Funding

A new Berkeley Research Group issue brief looked at trends in 340B investments.
The 340B program’s growth in recent decades has helped it attract a growing number of corporate and private equity investments, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Drug Industry-funded Think Tank Raises Questions About 340B Hospitals’ Charity Care

The Pioneer Institute for Public Policy Research compared 29 financially strong 340B hospitals/health systems’ performance on charity care in an Aug. 19 brief.
More transparency surrounding 340B hospital operations is needed to ensure drug discount savings are being used to improve patient care, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

After Failing To Disclose Conflict of Interest, JAMA Issues Correction to Piece Calling for Increased 340B Oversight and Transparency

JAMA corrected an opinion piece on the 340B program to disclose one author's drug industry ties, shortly after 340B Report reported on the omission.
Two weeks after publishing an opinion piece that called for increased 340B program oversight and provider transparency, JAMA issued a [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Two Researchers Call For More 340B Transparency, but JAMA Fails to Disclose Glaring Conflict of Interest

Two researchers authored a recent JAMA opinion piece calling for significant 340B reforms including asking Congress to consider limiting the program to low-income patients.
A recent opinion piece published in JAMA is calling for significant reforms to the 340B program, including more provider transparency, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Study Finds Oncology Markups at 340B Pediatric Hospitals; AHA Slams Study and Funder 

New research looked at the prices 340B-enrolled pediatric hospitals charged for pediatric oncology drugs.
The rates 340B pediatric hospitals negotiate with payers for new pediatric oncology drugs often exceed a medication’s average sale price, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

IRA Could ‘Crush the 340B Margin,’ Force Transparency into Program, Says Adam Fein of Drug Channels

Adam Fein, Ph.D., president of Drug Channels Institute, hosted a June 21 webinar that discussed the IRA's interaction with the 340B program.

The Inflation Reduction Act (IRA) may reduce 340B margins for certain high-cost drugs and drive more transparency into the program, an influential pharmaceutical supply chain analyst who has been a frequent 340B critic told an audience of stakeholders late last

Read More »

CBO Analysts Say Drug Spending Through 340B Grew 19% Annually From 2010 to 2021, 340B Champion Points Finger at Drug Industry

Congressional Budget Office logo
Spending on pharmaceuticals in the 340B drug discount program went from nearly $7 billion in 2010 to $44 billion by 2021—a 19% annual increase—according to preliminary Congressional Budget Office estimates released this week.
Spending on pharmaceuticals in the 340B drug discount program went from nearly $7 billion in 2010 to $44 billion by [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

340B Reform Could Generate Federal Savings, Says Consulting Firm That Has Conducted 340B Studies for Pharma Friendly Groups

Avalere's Milena Sullivan told 340B Report that it's important to understand "the impact 340B reform could have on federal spending."
A federal legislative overhaul of the 340B program could provide Medicare savings for the federal government, according to a review [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live